ATNM
Actinium Pharmaceuticals, Inc.
$0.97
-0.08 (-7.62%)
At close · Jul 8
Market Cap
$30.43M
Shares
31,374,991
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.97
Open$1.05
Day$0.96–1.05
52W$0.94–1.89
Avg vol 30d141K
Short int927K · 3.0% float · 5.7d
Short vol57%
DataJan 2020–Jul 2026
Filing10-Q · May 8
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−13%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−28%
trailing
YTD return
−29%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.96% of float · ▼ -14.3% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
55 holders — near 3-yr low, contrarian setup
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+11%
Y/Y
Gross margin
0%
EPS growth
+14%
Y/Y
Free cash flow
$-24.7M
Balance sheet
$48.0M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.96% of float · ▼ -14.3% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
55 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $1 · 4%
52-wk high $2
vs 200-day avg -24%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATNM
this stock
Actinium Pharmaceuticals, Inc.
|
$30.43M | -28.7% | — | — | 3.0% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATNM | -1.0% | -8.5% | -28.2% | -1.0% | -28.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -0.8% | -9.3% | -35.6% | -0.8% | -38.0% |